- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Tudor Investment Corp ET AL Invests $1.43 Million in Supernus Pharmaceuticals
Hedge fund buys 30,015 shares of specialty pharmaceutical company
Apr. 13, 2026 at 8:54am
Got story updates? Submit your updates here. ›
A major hedge fund's investment in Supernus Pharmaceuticals signals confidence in the specialty pharmaceutical company's growth potential.Rockville TodayTudor Investment Corp ET AL, a hedge fund, has bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 3rd quarter, according to a recent SEC filing. The fund purchased 30,015 shares of the specialty pharmaceutical company's stock, valued at approximately $1,434,000.
Why it matters
This investment by a major hedge fund signals confidence in Supernus Pharmaceuticals' growth potential and future performance in the specialty pharmaceutical market. It also highlights the continued interest from institutional investors in the company's product pipeline and financial outlook.
The details
According to the 13F filing, Tudor Investment Corp ET AL now owns about 0.05% of Supernus Pharmaceuticals. Several other hedge funds and institutional investors also recently modified their holdings in the company, including Jefferies Financial Group Inc., Ruffer LLP, and the Teacher Retirement System of Texas.
- The investment was made in the 3rd quarter of the most recent fiscal year.
- The 13F filing disclosing the transaction was submitted on April 13, 2026.
The players
Tudor Investment Corp ET AL
A hedge fund that has invested in Supernus Pharmaceuticals, purchasing 30,015 shares valued at approximately $1.43 million.
Supernus Pharmaceuticals, Inc.
A specialty pharmaceutical company focused on developing and commercializing central nervous system (CNS) therapies, including extended-release antiepileptic medications and a treatment for attention-deficit/hyperactivity disorder (ADHD).
The takeaway
This investment by Tudor Investment Corp ET AL underscores the continued institutional interest and confidence in Supernus Pharmaceuticals' ability to grow its specialty pharmaceutical business and deliver value to shareholders.
